상단메뉴 바로가기 본문 바로가기 본문 하위메뉴 바로가기 하단 바로가기

News

HOMENews

News

LyseNTech signed a joint research agreement with LegoChem Biosciences

라이센텍   /   2020-12-02

 Nov 30, 2020

 

LyseNTech signed a joint research agreement with LegoChem Biosciences on the 27th to develop a new antibiotic drug using endolysin.

With this contract,  LyseNTech and LegoChem Biosciences will jointly develop endolysin antibiotics for Gram negative bacteria as the first-in-class new drug.